Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

TIS21/BTG2 inhibits breast cancer growth and progression by differential regulation of mTORc1 and mTORc2–AKT1–NFAT1–PHLPP2 signaling axis

TIS21/BTG2 inhibits breast cancer growth and progression by differential regulation of mTORc1 and... Purpose It has been reported that PI3K/AKT pathway is altered in various cancers and AKT isoforms specifically regulate cell growth and metastasis of cancer cells; AKT1, but not AKT2, reduces invasion of cancer cells but maintains cancer /BTG2 growth. We propose here a novel mechanism of the tumor suppresser, TIS21 , that inhibits both growth and invasion of triple negative breast cancer cells via AKT1 activation by differential regulation of mTORc1 and mTORc2 activity. /BTG2 Methods Transduction of adenovirus carrying TIS21 gene and transfection of short interfering RNAs were employed /BTG2 to regulate TIS21 gene expression in various cell lines. Treatment of mTOR inhibitors and mTOR kinase assays can /BTG2 evaluate the role of mTORc in the regulation of AKT phosphorylation at S473 residue by TIS21 in breast cancer cells. /BTG2 Open data and immunohistochemical analysis were performed to confirm the role of TIS21 expression in various human breast cancer tissues. /BTG2 Results We observed that TIS21 inhibited mTORc1 activity by reducing Raptor-mTOR interaction along with upregu- S473 lation of tsc1 expression, which lead to significant reduction of p70S6K activation as opposed to AKT1 , but not AKT2, /BTG2 S473 phosphorylation via downregulating PHLPP2 (AKT1-specific phosphatase) in breast cancers. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Cancer Research and Clinical Oncology Springer Journals

TIS21/BTG2 inhibits breast cancer growth and progression by differential regulation of mTORc1 and mTORc2–AKT1–NFAT1–PHLPP2 signaling axis

Loading next page...
 
/lp/springer_journal/tis21-btg2-inhibits-breast-cancer-growth-and-progression-by-ILYRk0IPEt

References (54)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Cancer Research; Internal Medicine; Hematology
ISSN
0171-5216
eISSN
1432-1335
DOI
10.1007/s00432-018-2677-6
pmid
29808317
Publisher site
See Article on Publisher Site

Abstract

Purpose It has been reported that PI3K/AKT pathway is altered in various cancers and AKT isoforms specifically regulate cell growth and metastasis of cancer cells; AKT1, but not AKT2, reduces invasion of cancer cells but maintains cancer /BTG2 growth. We propose here a novel mechanism of the tumor suppresser, TIS21 , that inhibits both growth and invasion of triple negative breast cancer cells via AKT1 activation by differential regulation of mTORc1 and mTORc2 activity. /BTG2 Methods Transduction of adenovirus carrying TIS21 gene and transfection of short interfering RNAs were employed /BTG2 to regulate TIS21 gene expression in various cell lines. Treatment of mTOR inhibitors and mTOR kinase assays can /BTG2 evaluate the role of mTORc in the regulation of AKT phosphorylation at S473 residue by TIS21 in breast cancer cells. /BTG2 Open data and immunohistochemical analysis were performed to confirm the role of TIS21 expression in various human breast cancer tissues. /BTG2 Results We observed that TIS21 inhibited mTORc1 activity by reducing Raptor-mTOR interaction along with upregu- S473 lation of tsc1 expression, which lead to significant reduction of p70S6K activation as opposed to AKT1 , but not AKT2, /BTG2 S473 phosphorylation via downregulating PHLPP2 (AKT1-specific phosphatase) in breast cancers.

Journal

Journal of Cancer Research and Clinical OncologySpringer Journals

Published: May 28, 2018

There are no references for this article.